Contact your healthcare provider if: The bad taste is severe, persistent, or significantly affecting your quality of life, nutrition, or ability to take the medication as prescribed You experience taste changes accompanied by other concerning symptoms such as severe nausea, persistent vomiting, signs of dehydration, abdominal pain, or difficulty swallowing You notice signs of oral infection, including painful sores, white patches in your mouth, swollen or bleeding gums, or fever The taste disturbance is accompanied by symptoms that might suggest gastroesophageal reflux disease (GERD), such as heartburn, chest discomfort, or regurgitation of food You develop new neurological symptoms alongside taste changes, such as facial numbness, difficulty speaking, or changes in smell perception, which could indicate conditions requiring urgent evaluation Seek immediate medical attention and stop taking semaglutide if you experience: Severe, persistent abdominal pain, sometimes radiating to the back, which could indicate pancreatitis Right upper abdominal pain, fever, or yellowing of skin/eyes, which might suggest gallbladder disease Severe vomiting, inability to keep fluids down, dizziness, or reduced urination, which could indicate dehydration or kidney problems Your healthcare provider may: Conduct a thorough oral examination or refer you to a dentist to rule out dental causes Review your complete medication list to identify potential drug interactions or other medications that might contribute to dysgeusia Order laboratory tests to check for nutritional deficiencies (such as zinc or vitamin B12) or assess kidney and liver function Evaluate for gastroesophageal reflux and consider treatment if indicated Assess whether dose adjustment or temporary discontinuation of semaglutide is appropriate Consider whether the benefits of continuing semaglutide outweigh the discomfort from taste changes, or discuss alternative treatment options Except in the emergency situations noted above, do not adjust your dose or discontinue semaglutide without medical guidance, as this may lead to worsening glycemic control in patients with diabetes or weight regain in those using it for weight management

Both semaglutide and tirzepatide are now off the FDA's official shortage list
ISBN 978-3-030-92391-4
Physiological Effects: Released endogenous hGH then exerts its effects on target tissues, promoting growth, protein synthesis, and metabolic processes
"The stock reaction felt disproportionate, but there's just no buyers that are offsetting the sellers," Field said, noting that some U.S
A meta-analysis also suggests an increased risk of gallbladder or biliary disorders with prolonged or high-dose use (50)